Successful Treatment of Immune Thrombocytopenic Purpura with Intracranial Hemorrhaging and Duodenal Bleeding Following SARS-CoV-2 Vaccination.
Intern Med
; 61(12): 1891-1895, 2022 Jun 15.
Article
in English
| MEDLINE | ID: covidwho-1951861
ABSTRACT
Several vaccines have been developed for coronavirus disease 2019 - caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) - in record time. A few cases of immune thrombocytopenic purpura (ITP) following SARS-CoV-2 vaccination have been reported. We herein report a 90-year-old man who received the Pfizer-BioNTech SARS-CoV-2 vaccine (BNT162b2) and developed severe thrombocytopenia with intracranial hemorrhaging and duodenal bleeding, consistent with vaccine-related ITP. He was successfully treated with intravenous immunoglobulin, prednisolone, and eltrombopag and discharged without cytopenia. Vaccine-related ITP should be suspected in patients presenting with abnormal bleeding or purpura after vaccination.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Thrombocytopenia
/
Purpura, Thrombocytopenic, Idiopathic
/
Intracranial Hemorrhages
/
COVID-19
/
BNT162 Vaccine
Type of study:
Case report
Topics:
Vaccines
Limits:
Humans
/
Male
Language:
English
Journal:
Intern Med
Journal subject:
Internal Medicine
Year:
2022
Document Type:
Article
Affiliation country:
Internalmedicine.9199-21
Similar
MEDLINE
...
LILACS
LIS